МЕСТО КОМБИНИРОВАННОЙ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ФИКСИРОВАННЫХ КОМБИНАЦИЙ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ
https://doi.org/10.20996/1819-6446-2010-6-4-550-557
Аннотация
Обcуждается место фиксированных комбинаций в лечении артериальной гипертонии (АГ). Рассмотрены теоретические и практические аспекты комбинированной терапии, принципы рациональной комбинированной терапии. Проанализированы современные рекомендации по использованию фиксированных комбинаций, в том числе в качестве стартовой антигипертензивной терапии. Приведена классификация комбинаций и проанализированы преимущества и ограничения использования некоторых из них. Освещено место фиксированной комбинации бета-адерноблокатора бисопролола и тиазидного диуретика гидрохлортиазида (Лодоза) в лечении АГ.
Об авторах
Ж. Д. Кобалава
Российский университет дружбы народов
Россия
Россия
профессор, д.м.н., заведующая кафедрой кардиологии и клинической фармакологии факультета повышения квалификации
Москва, 117198, ул. Миклухо-Маклая, д.6
Ю. В. Котовская
Российский университет дружбы народов
Россия
Россия
профессор, д.м.н., профессор кафедры кардиологии и клинической фармакологии факультета повышения квалификации
Москва, 117198, ул. Миклухо-Маклая, д.6
Список литературы
1. Диагностика и лечение артериальной гипертензии, Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2: 1-32.
2. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252
3. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6):1105-1187
4. Mancia G., Laurent S.,Agabiti-Rosei E. et al.Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18(6):308-47.
5. GradmanA.H., Basile J.N., Carter B.L., Bakris G.L. on behalf oftheAmerican Society ofHypertension Writing Group. Combination therapy in hypertension. ASH Position Article. J Am Soc Hypertens 2010;4(1): 42–50
6. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427-35.
7. Neaton J.D., Grimm R.H. Jr., Prineas R.J. et al. Treatment of Mild Hypertension Study. JAMA 1993;270(6):713-24.
8. ALLHAT Officers and Coordinators fortheALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981–97.
9. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principalresults oftheHypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351(9118):1755–62.
10. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):995–1003.
11. Dickerson J.E., Hingorani A.D., Ashby M.J. et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353(9169):2008-13.
12. Mourad J., Waeber B., Zinnad F. et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004;22(12):2379–86.
13. Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials. Am J Med 2009;122(3):290–300.
14. Sica D.A. Rationale forfixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62(3):443–62
15. Fung V., Huang J., Brand R. et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29(5): 972–84.
16. Dunbar-Jacob. NationalHeart, Lung and Blood Institute Implementation Conference 2009.
17. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. et al. Fixeddose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120(8):713–719.
18. Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363(9426):2049–51.
19. Mancia G., Messerli F., Bakris G. et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50(2):299–305.
20. Jamerson K., Bakris G.L., Dahlof B. et al; for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16(2):80–86.
21. Feldman R.D., Zou G.Y., Vandervoort M.K. et al. A simplified approach to the treatment of uncomplicated hypertension: a clusterrandomized, controlled trial. Hypertension 2009;53(4): 646–653.
22. Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manage Care 2000;9(9 Suppl):2–6.
23. Egan B.M. Fixed-dose combinations and hypertension control in community-based practices: application of the ‘‘keep-it-simple’’ principle. Hypertension 2009; 53(4):598–599.
24. Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547–59.
25. Izzo R., de Simone G., Chinali M. et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care 2009;32(5):845–50.
26. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362(16): 1477-90.
27. Frishman W.H., Brizzynski B.S., Coulson L.R. et al. A multifactorial trial design to assess cjmbination therapy in hypertension: treatment with Bissoprolol andHydrochlorothiazide. Arch Intern Med 1994; 154(13): 1461-8.
28. Frishman W.H., Burris J.F., Mroczek W.J. et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995;35(2):182-8.
29. Lewin A.J., Lueg M.C., Targum S., Cardenas P. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. Clin Cardiol 1993;16(10):732-6.
30. Benetos A., Cosoli S., Safavian A. et al. Efficacy, safety and effects on quality of life of Bisoprolol/Hydrochlorothiazide versus Amlodipine in elderly patients with systolic hypertension. Am Heart J 2000; 140(4): e14.
31. Rejnmark L., Vestergaard P., Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium channel blockers is associated with a reduced fracture risk: a nationwide case–control study.JHypertens2006; 24(3):581–589
32. Prisant L.M., NeutelJ.M., PapademetriouV. et al. Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies. Am J Ther 1998;5(5):313-21.
33. Papademetriou V., Neutel J., Naravan P. et al. Comparison of Bisoprolol and low doseHydrochlorothiazide combination with Losartan, alone or in combination with Hydrochlorothiazide, in the treatment of hypertension: a double blind, randomized, placebo controlled trial. Cardiovasc Rev Rep 1999;19(12):19-28.
34. Prisant L.M., Weir M.R., Frishmanwh et al. Self reported Sexual Dysfunction in Men and Woman Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999;1(1):22-26.
Рецензия
Для цитирования:
Кобалава Ж.Д., Котовская Ю.В. МЕСТО КОМБИНИРОВАННОЙ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ФИКСИРОВАННЫХ КОМБИНАЦИЙ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ. Рациональная Фармакотерапия в Кардиологии. 2010;6(4):550-557. https://doi.org/10.20996/1819-6446-2010-6-4-550-557
For citation:
Kobalava Z.D., Kotovskaya J.V. IMPLICATION OF THE FIXED COMBINATIONS IN THE HYPERTENSION TREATMENT. Rational Pharmacotherapy in Cardiology. 2010;6(4):550-557. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-4-550-557
Просмотров:
670
Послать статью по эл. почте 